Ladenburg Thalmann Expands Investment Banking Platform with Biotechnology Specialist Dr. Aydin Huseynov, M.D., CFA

NEW YORK--(BUSINESS WIRE)--Ladenburg Thalmann & Co. Inc. (“Ladenburg Thalmann”), a leading middle-market investment bank providing investment banking, equity research, and institutional sales and trading services, today announced that Aydin Huseynov, M.D., CFA, has joined the firm's Healthcare Investment Banking Group as Managing Director, Biotechnology Investment Banking Specialist.

Dr. Huseynov will focus on the continued expansion of Ladenburg's biotechnology investment banking platform including strengthening Ladenburg's biotechnology relationships, leveraging his medical background and expertise to analyze clinical and market data, and providing his insight to management teams on strategic considerations related to clinical development and regulatory pathways.

Dr. Huseynov brings deep expertise across biotechnology, clinical development, and capital markets. Prior to joining the Healthcare Investment Banking Group, he served as Managing Director in Equity Research at Ladenburg for the last four years, where he covered the biotechnology sector and now transitions to a dedicated focus on investment banking, where he developed broad relationships within the biotechnology sector, including with company management teams and institutional investors.

"Aydin's medical and scientific background, together with his deep knowledge of the biotechnology landscape, further strengthens our ability to engage with innovative companies and support their growth," said Barry Steiner, Co-President and Co-CEO of Ladenburg Thalmann. "We are pleased to have him join our healthcare investment banking platform."

"We are excited to welcome Aydin to our growing healthcare investment banking team," said Nicholas Stergis, Co-Head of Investment Banking. "Aydin brings a unique combination of medical training, biotechnology expertise, and strong corporate and investor relationships across the sector. His experience will help us deepen our engagement with innovative biotechnology companies and expand our advisory and capital markets capabilities."

Dr. Huseynov holds an M.D., an MBA from Duke University, and is a CFA charter-holder. He previously worked in strategy consulting at Syneos Health Consulting, in investment banking at MTS Health Partners, and has held biotechnology equity research roles at Oppenheimer, The Benchmark Company, and Ladenburg Thalmann.

Dr. Huseynov is based in Ladenburg Thalmann's New York City office.

For more information, please visit www.ladenburg.com.

About Ladenburg Thalmann:

Ladenburg Thalmann & Co. Inc. is a full-service, diversified financial services firm that offers a comprehensive suite of investment banking and capital markets products and services, including equity and debt capital raising, mergers and acquisitions, corporate finance advisory, and fairness opinions. Ladenburg was established in 1876 and has been a member of the New York Stock Exchange since 1879.

About Osaic

Osaic, Inc. (“Osaic”), a portfolio company of Reverence Capital Partners, is one of the nation’s largest providers of wealth management strategies, supporting over 10,000 financial professionals. Osaic’s mission is to empower entrepreneurial advisors to create leading wealth management solutions that enhance lives and legacies. Visit www.osaic.com to learn more.

Securities and investment advisory services are offered through the firms: Osaic Wealth, Inc. and Osaic Institutions, Inc., broker-dealers, registered investment advisers, and members of FINRA and SIPC. Securities are offered through Osaic Services, Inc. and Ladenburg Thalmann & Co., broker-dealers and members of FINRA and SIPC. Advisory services are offered through Ladenburg Thalmann Asset Management, Inc., Osaic Advisory Services, LLC, and CW Advisors, LLC, registered investment advisers. Advisory programs offered by Osaic Wealth, Inc. are sponsored by VISION2020 Wealth Management Corp., an affiliated registered investment adviser.